|Bid||6.41 x 30000|
|Ask||6.66 x 30000|
|Day's Range||6.70 - 6.73|
|52 Week Range||2.46 - 10.02|
|Beta (5Y Monthly)||2.79|
|PE Ratio (TTM)||N/A|
|Earnings Date||Feb 27, 2023 - Mar 03, 2023|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||20.57|
CAMBRIDGE, Mass., November 22, 2022--Seres Therapeutics, Inc. (Nasdaq: MCRB), a leading microbiome therapeutics company, today announced that it will host an investor webcast to discuss the planned commercialization approach and market opportunity for therapeutic candidate SER-109 in recurrent C. difficile infection (rCDI) on Thursday, December 8, 2022, at 8:30 a.m. ET and is expected to be approximately one hour in duration.
Seres Therapeutics ( NASDAQ:MCRB ) Third Quarter 2022 Results Key Financial Results Revenue: US$3.44m (down 97% from 3Q...
Seres Therapeutics (MCRB) delivered earnings and revenue surprises of -8.89% and 71.97%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?